Ortiz Zegarra César Antonio, Custodio Sánchez Piero, Rojas de la Cuba Paol, Mori Pinedo Gorki E, Coloma Araniya Ricardo, Gonzales Álvarez Bertha Aidee, Nolte Rickards Christian
Médico asistente del Servicio de Cardiología Intervencionista. Instituto Nacional Cardiovascular - INCOR. Lima. Perú. Servicio de Cardiología Intervencionista Instituto Nacional Cardiovascular - INCOR Lima Perú.
Secretario de ética de la Sociedad Peruana de Hemodinámica e Intervencionismo Endovascular (SOPHIE). Sociedad Peruana de Hemodinámica e Intervencionismo Endovascular (SOPHIE).
Arch Peru Cardiol Cir Cardiovasc. 2020 Dec 31;1(4):222-228. doi: 10.47487/apcyccv.v1i4.86. eCollection 2020 Oct-Dec.
Chronic coronary syndrome (SCC) previously known as stable coronary disease, is the main cause of mortality in the world, and it is one of the most important in Peru. This pathology has a dynamic nature that results in different clinical scenarios that can be modified through various therapeutic options, one of which is coronary interventional treatment, mainly in patients with high ischemic risk defined as ischemia greater than 10% of the entire left ventricular mass. For this reason, we have analyzed the most relevant and current information available, concluding that the treatment of high ischemic risk´s chronic coronary syndrome, after an individual evaluation, would correspond to an invasive management from the beginning, although it would not impact on mortality or cardiovascular events, it would contribute to improve quality of life; also we should consider the incomplete availability of all the therapeutic options for the symptomatic management of this disease, the limited access to the management of acute cardiovascular events in our country, as well as the risk of adverse effects and drug interactions.
慢性冠状动脉综合征(SCC)以前被称为稳定型冠心病,是全球主要的死亡原因,也是秘鲁最重要的死亡原因之一。这种病理具有动态性,会导致不同的临床情况,可通过各种治疗选择进行改善,其中之一是冠状动脉介入治疗,主要针对缺血风险高的患者,即缺血面积大于整个左心室质量的10%。因此,我们分析了现有的最相关和最新信息,得出结论:经过个体评估后,对于缺血风险高的慢性冠状动脉综合征患者,一开始就应采用侵入性治疗,尽管这不会影响死亡率或心血管事件,但有助于提高生活质量;我们还应考虑到针对该疾病症状管理的所有治疗选择并不完全可用、我国急性心血管事件管理的可及性有限,以及不良反应和药物相互作用的风险。